When complexed with a bispecific CD30/CD16 antibody (AFM13), the expanded pre-activated cord-blood NK cells also exhibited enhanced responses against CD30+ lymphomas in vitro and in vivo. This evidence concerns the gene FCGR3A and lymphoma.